Pacira announces CMS established additional payment for iovera in outpatient

Pacira (PCRX) BioSciences announced that the Centers for Medicare and Medicaid Services, CMS, issued its final Medicare Hospital Outpatient Prospective Payment System, OPPS, and Medicare Ambulatory Surgical Center, ASC, Payment System rule for 2025, which implements the Non-Opioids Prevent Addiction in the Nation, NOPAIN, Act that mandated separate Medicare payment for qualifying non-opioid drugs and devices. In the final rule, CMS confirmed that both EXPAREL and iovera qualify as eligible non-opioid pain management products under the NOPAIN Act. Hospital outpatient departments, HOPDs, and ASCs that use these products will receive additional Medicare reimbursement beginning January 1, 2025.